Lazcluze (Lazertinib) for EGFR-Mutated Lung Cancer: What to Expect

"My Report Says EGFR-Positive." So What Happens Next?

Written By: Nitin Goswami, Senior Medical Content Writer  |  Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)

You've had the biopsy, you've waited for the results, and then came a line on the report that changes the conversation: EGFR exon 19 deletion, or EGFR L858R. For a lot of people, it's oddly good news in the middle of bad news, because it means there's a targeted treatment built for exactly this change.

One of those treatments is Lazcluze (lazertinib), a tablet taken once a day together with an infusion medicine called amivantamab (Rybrevant). It works well in trials. It also comes with a rulebook that's much easier to follow if you hear it before you start: a skin and nail routine, a plan for blood clots, and a few things to watch for in your lungs, liver, and eyes.

The U.S. FDA approved Lazcluze on August 19, 2024, together with amivantamab, as first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has one of those two EGFR mutations. In this guide we'll go through what the mutations mean, what the trials found, what the first months usually look like, and what to ask your oncologist.

Lazcluze at a Glance

First, What Does "EGFR-Mutated" Actually Mean?

The Two Mutations Lazcluze Is For

EGFR is a protein on the surface of cells that tells them to grow. In some lung cancers a change in the EGFR gene leaves that signal switched on all the time. Lazcluze is approved for two specific changes:

• EGFR exon 19 deletions
• EGFR exon 21 L858R substitution mutations

In the main trial, 60% of participants had an exon 19 deletion and 40% had the L858R mutation. Other EGFR changes are treated differently, so it's worth asking your oncologist exactly which one your report shows.

How Is It Tested?

• The mutation has to be found using an FDA-approved test, on either a tumor sample or a blood (plasma) sample
• If a blood test doesn't find the mutation, the label says to test the tumor tissue instead, since a blood test can miss it

How Common Is It, Especially in India?

• A 2023 review of 26 Indian studies found that EGFR mutations are present in about 24.2% of advanced NSCLC, and about 28.7% of adenocarcinoma, one of the main NSCLC subtypes (Asia-Pacific Journal of Clinical Oncology). Individual studies ranged widely, from 11.9% to 51.8%
• In the main Lazcluze trial, 69% of participants had never smoked and 61% were women. If you've never smoked and have been wondering how this could happen to you, you're in good company in that trial

Lung Cancer in Numbers

These numbers can be hard to read when they describe your own diagnosis. But they do show that you're far from alone, and that there's a lot of research behind the treatment you're being offered. Each figure names its source and year.

How Many People Are Affected?

• Worldwide (GLOBOCAN 2024, WHO/IARC): 2,637,005 new cases and 1,861,839 deaths in a year. Lung cancer is the most common cancer in the world (12.8% of all cancers) and the leading cause of cancer death (19.1%)
• India (GLOBOCAN 2024): 112,659 new cases and 98,687 deaths a year. It's India's 3rd most common cancer (7.2%) but the leading cause of cancer death (10.9%). Among men it's the 2nd most common cancer (79,048 cases, 10.1% of cancers in men)
• United States (SEER, 2026 estimate): 229,410 new cases and 124,990 deaths, with an estimated 661,853 people living with lung cancer in 2023 and a median age at diagnosis of 71
• The main type: about 80% to 85% of lung cancers are non-small cell lung cancer (American Cancer Society)

India's figures are modelled from regional cancer registries rather than counted nationwide, so treat them as a reliable ballpark, not an exact head-count.

Why Stage Matters

• In the US, 24% of lung cancers are found while still confined to the lung, 21% have reached nearby lymph nodes, and 51% have already spread to distant organs (SEER, 2016–2022)
• Five-year survival is about 65.5% when localized, 38.2% when regional, and 10.5% once it has spread, with 29.5% across all stages

These are relative survival figures, which compare people with the cancer to the general population, and they describe large groups from years ago rather than any one person. Targeted treatments like the one in this guide are newer than most of that data, which is exactly why the trial results below matter.

Two Medicines, One Plan

What Each One Does

• Lazertinib (Lazcluze) is a third-generation EGFR tyrosine kinase inhibitor, a tablet that blocks the mutated EGFR signal inside the cancer cell
• Amivantamab (Rybrevant) is a bispecific antibody, given by infusion, that targets both EGFR and MET

Lazcluze is approved only in combination with amivantamab for this use. You can read about the infusion medicine on our Rybrevant page.

What a Typical Schedule Looks Like

• Lazcluze: one 240 mg tablet by mouth once a day, with or without food
• Amivantamab: by infusion, at a dose of 1,050 mg if you weigh less than 80 kg or 1,400 mg if you weigh 80 kg or more. It's given once a week for the first 4 weeks, then every 2 weeks starting at week 5
• On infusion days: take your Lazcluze tablet any time before the amivantamab infusion
• How long: until the cancer progresses or the side effects become unacceptable

What the Main Trial Found

MARIPOSA: The Trial Behind the Approval

MARIPOSA enrolled people whose EGFR-mutated lung cancer had not yet been treated. Patients were randomly assigned to Lazcluze plus amivantamab (429 patients) or to osimertinib (429 patients), another EGFR tablet already used for this cancer (a third group of 216 patients received lazertinib alone) (New England Journal of Medicine, 2024).

How Long Before the Cancer Grew Again

• Median progression-free survival was 23.7 months with Lazcluze plus amivantamab and 16.6 months with osimertinib (hazard ratio 0.70)

How Long People Lived

• In the final survival analysis, the combination reduced the risk of death by 25% compared with osimertinib (hazard ratio 0.75). The median wasn't reached in the combination group, versus 36.7 months with osimertinib
• Three years in, 60% of people on the combination were alive, compared with 51% on osimertinib (New England Journal of Medicine, 2025)

How Many Tumors Shrank, and for How Long

• A confirmed response was seen in 78% of people on the combination and 73% on osimertinib
• Among people who responded, the response lasted a median of 25.8 months versus 16.7 months, and 68% of responses lasted 12 months or longer versus 57%

What About Asian Patients?

Because 58% of MARIPOSA participants were Asian, researchers looked at that group separately. Among the 629 Asian participants, median overall survival wasn't reached with the combination, versus 38.4 months with osimertinib (hazard ratio 0.74) (Lung Cancer, 2026). That's a subgroup analysis, so treat it as encouraging rather than definitive.

The Price of the Extra Benefit

Let's be straight about this. The combination did better on survival, and it also caused more side effects than osimertinib.

• Grade 3 or higher side effects occurred in 80% of people on the combination versus 52% on osimertinib
• According to the FDA label, serious side effects occurred in 49% of patients on the combination, and 7% had fatal adverse reactions
• Lazcluze was interrupted because of side effects in 72% of patients, reduced in 42%, and permanently stopped in 21%

Whether the extra benefit is worth the extra side effects is a personal decision. It depends on your age, your general health, and what matters most to you, and it's a conversation for you and your oncologist.

The Part Nobody Warns You About: Skin, Clots, and Everything Else

This is the section to read closely. Most of the trouble with this combination is predictable, and most of it can be prepared for.

Skin and Nails

How Common Is It?

• Rash affected 86% of people on the combination (26% at grade 3), compared with 48% on osimertinib
• Nail problems (nail toxicity) affected 71% (11% at grade 3), compared with 34% on osimertinib
• Dry skin (25%) and itching (24%) were also common
• Rash usually starts early. The median time to onset was 14 days

The Prevention Routine

The label recommends starting a skin routine on day one, and a separate trial suggests it makes a real difference.

The First 12 Weeks

• An oral antibiotic (doxycycline or minocycline, 100 mg twice a day) starting on day 1
• A non-comedogenic moisturizer (ceramide-based, or another long-lasting formula without drying agents) on your face and body, but not the scalp
• A 4% chlorhexidine wash for your hands and feet once a day

The Following 9 Months

• Once the antibiotic course ends, 1% clindamycin lotion on the scalp once a day
• Keep up the moisturizer and the hand and foot wash
• Limit sun exposure during treatment and for 2 months after, wear protective clothing, and use a broad-spectrum UVA/UVB sunscreen

Does the Routine Actually Work?

In the COCOON trial, 201 people on this combination were randomly assigned to an enhanced skin routine like the one above or to standard care. By week 12, grade 2 or higher skin reactions had occurred in 42% of the group using the enhanced routine, versus 75% in the standard care group (Journal of Thoracic Oncology, 2025).

If the Rash Gets Worse

Grade 2

Your team starts supportive care. If there's no improvement after 2 weeks, the amivantamab dose is reduced while Lazcluze continues at the same dose, and things are rechecked every 2 weeks.

Grade 3

Both medicines are paused and supportive care begins. Once you recover, Lazcluze restarts at the same or a lower dose and amivantamab at a reduced dose. If there's no improvement within 2 weeks, both are stopped permanently.

Grade 4, Including Blistering or Peeling

Amivantamab is permanently stopped. Lazcluze is paused until you recover, then restarted at a reduced dose.

Blood Clots

• Venous blood clots (in the leg or lungs) occurred in 36% of people on the combination, with 10% at grade 3 and 0.5% at grade 4. There were two fatal cases (0.5%)
• Most happened in the first four months of treatment
• Because of that, the label recommends taking a blood thinner as prevention for the first four months. Vitamin K antagonists (warfarin-type medicines) are not recommended for this
• If there are no signs of a clot after four months, your doctor may consider stopping the blood thinner
• Tell your care team straight away about any signs of a clot

Lungs

• Interstitial lung disease (ILD) or pneumonitis, an inflammation of the lungs, occurred in 3.1% of patients (1.0% at grade 3, 0.2% at grade 4), with one fatal case
• New or worsening breathlessness, cough, or fever needs to be reported immediately. Treatment is paused if ILD is suspected and stopped permanently if it's confirmed

Liver

• Liver problems occurred in 49% of patients, with 9.3% at grade 3 and 0.5% at grade 4
• Liver tests (ALT, AST, and bilirubin) are done before you start and during treatment as needed. Contact your team right away about any signs of liver trouble

Eyes

• Eye problems, including keratitis, occurred in 16% of patients, with 0.7% at grade 3 or 4
• New or worsening eye symptoms should be seen by an eye specialist promptly. Stop using contact lenses until the symptoms have been evaluated

Infusion Reactions

• Infusion-related reactions to amivantamab occurred in 63% of patients, with 6% at grade 3 or 4

Other Common Side Effects

These occurred in at least 1 in 5 patients on the combination:

• Musculoskeletal pain: 47%
• Swelling (edema): 43%
• Mouth sores (stomatitis): 43%
• Tingling or numbness (paresthesia): 35%
• Fatigue: 32%
• Diarrhea: 31%
• Constipation: 29%
• COVID-19: 26%
• Bleeding (hemorrhage): 25%
• Decreased appetite: 24%
• Nausea: 21%

Taking Lazcluze Day to Day

The Practical Bits

• Swallow the tablet whole. Don't crush, split, or chew it
• Missed a dose? If it's within 12 hours, take it. If more than 12 hours have passed, skip it and take the next dose at the usual time
• Vomited after a dose? Don't take another, just take the next dose at the usual time
• Storage: at room temperature, 20°C to 25°C (68°F to 77°F)
• Tablets: they come in 80 mg and 240 mg strengths, and the 240 mg tablet comes in a bottle of 30

If You Need a Lower Dose

• First reduction: 160 mg once a day (two 80 mg tablets)
• Second reduction: 80 mg once a day (one 80 mg tablet)
• If you can't tolerate 80 mg, Lazcluze is stopped

Medicines That Interact

• Avoid strong and moderate CYP3A4 inducers, because they can lower Lazcluze levels and weaken its effect
• Lazcluze can raise the levels of certain CYP3A4 and BCRP substrates, so your doctor may need to monitor other medicines you take
• Tell your oncologist about everything you take, including supplements

Pregnancy and Breastfeeding

• Lazcluze can cause fetal harm. Women who could become pregnant, and men whose partners could become pregnant, should use effective contraception during treatment and for 3 weeks after the last dose
• Breastfeeding isn't advised during treatment and for 3 weeks after the last dose
• The label also notes a possible risk to fertility

Questions Worth Taking to Your Next Appointment

You don't have to remember all of this. A few questions to get the conversation started:

• Which EGFR mutation do I have, and was it found on a tumor sample or a blood test?
• Who will manage my skin routine, and when does it start?
• Will I take a blood thinner, and for how long?
• How often will I need liver tests and check-ups?
• Which symptoms, in my lungs, eyes, or legs, should make me call you straight away?
• How does this combination compare with osimertinib for someone in my situation?

Getting Lazcluze in India

The regulated route for an individual patient is a Named Patient Program, which imports a medicine for one specific patient against a doctor's prescription. Through NPP, Lazcluze is sourced directly from Janssen's authorized supply chain. In practice, you'll need:

• A valid prescription from your treating oncologist
• Confirmation of your EGFR exon 19 deletion or exon 21 L858R mutation using an FDA-approved test
• Supporting clinical documentation, as required by Indian regulatory authorities

The Lazcluze product page explains the process, and our oncology access program covers other cancer medicines on the same pathway. If your lung cancer carries a different biomarker, such as KRAS G12C, our guide to Lumakras may be the one you need.

Have Your Reports Handy? Let's Talk It Through

Whether Lazcluze is the right fit depends on your mutation report and your treatment plan. Send our team your EGFR test result, your histopathology report, and your oncologist's recommendation, and we'll explain what the access process would involve. There's no cost and no obligation. Start the conversation here.

The Short Version

• Lazcluze (lazertinib) is a once-daily EGFR inhibitor tablet, approved by the FDA on August 19, 2024, together with amivantamab (Rybrevant), for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
• Lung cancer is the leading cause of cancer death in India, with 112,659 new cases a year (GLOBOCAN 2024), and EGFR mutations are found in roughly 1 in 4 Indian NSCLC patients.
• In MARIPOSA, the combination gave a median of 23.7 months without progression versus 16.6 months with osimertinib, and a 25% lower risk of death.
• The extra benefit comes with more side effects: grade 3 or higher events in 80% versus 52%.
• Rash (86%), nail problems (71%), and blood clots (36%) are the big three, and there's a plan for each: a skin routine from day one, and a blood thinner for the first four months.
• Contraception is needed during treatment and for 3 weeks after the last dose.
• Lazcluze can be accessed through a Named Patient Program with your oncologist's prescription and your mutation report.

Frequently Asked Questions

Can I take Lazcluze on its own, without Rybrevant?

Not for this use. Lazcluze is approved only in combination with amivantamab for first-line treatment. In the trial, lazertinib alone was studied as a comparison arm, and the label describes it as an unapproved regimen for NSCLC.

What if my report shows a different EGFR mutation?

Lazcluze is approved for exon 19 deletions and the exon 21 L858R mutation only. Other EGFR changes are handled differently, so ask your oncologist how your specific result affects your options.

Will I definitely get a rash?

Most people do: 86% in the trial. But it's usually predictable. It tends to start within a couple of weeks, and the prevention routine (antibiotic, moisturizer, hand and foot wash, scalp lotion, sun protection) is designed to lessen it. In the COCOON trial the enhanced routine cut grade 2 or higher skin reactions from 75% to 42% at 12 weeks.

Do I have to take a blood thinner?

The label recommends preventive blood thinners for the first four months, because most clots happened in that window. Warfarin-type medicines aren't recommended for this. Your oncologist chooses the medicine and decides when to stop.

Can I go out in the sun?

You'll want to limit direct sun exposure during treatment and for 2 months afterward. Wear protective clothing and use a broad-spectrum UVA/UVB sunscreen when you do go out.

How long will I be on it?

Until the cancer progresses or side effects become unacceptable. In the trial, 73% of patients had been on Lazcluze for more than a year.

How do I get Lazcluze in India?

Through a regulated Named Patient Program. It imports the medicine for a specific patient, with a valid prescription from the treating oncologist, confirmation of your EGFR mutation using an FDA-approved test, and supporting clinical documentation.

Is it safe to buy it from an online pharmacy or a seller abroad?

Please be careful. Cancer medicines sold outside regulated channels can be counterfeit, expired, or stored badly, and a tablet that looks right tells you nothing about what's actually in it. Named Patient Program sources Lazcluze from Janssen's authorized supply chain, against a valid oncologist's prescription, with documentation and batch traceability, so what reaches you can be traced back to the manufacturer.

Every lung cancer journey looks a little different, and the right treatment depends on your mutation, your health, and what matters to you. Use this page to prepare better questions, and let your oncologist make the final call.

References

1. U.S. Food and Drug Administration. FDA Approves Lazertinib with Amivantamab-vmjw for Non-Small Lung Cancer, August 19, 2024.
2. DailyMed (National Library of Medicine). LAZCLUZE (lazertinib) Prescribing Information.
3. Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC (MARIPOSA), New England Journal of Medicine 2024;391.
4. Yang JC, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC, New England Journal of Medicine 2025;393.
5. Cho BC, et al. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial, Journal of Thoracic Oncology 2025;20.
6. Hayashi H, et al. Overall Survival for Amivantamab Plus Lazertinib versus Osimertinib as First-Line Treatment in Asian Participants with EGFR-Mutant Advanced NSCLC: A MARIPOSA Subset Analysis, Lung Cancer 2026;214.
7. Raman R, et al. Prevalence of Highly Actionable Mutations Among Indian Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, Asia-Pacific Journal of Clinical Oncology 2023;19.
8. National Cancer Institute SEER Program. Cancer Stat Facts: Lung and Bronchus Cancer.
9. American Cancer Society. What Is Lung Cancer?
10. International Agency for Research on Cancer (WHO). GLOBOCAN 2024: World Fact Sheet.
11. International Agency for Research on Cancer (WHO). GLOBOCAN 2024: India Fact Sheet.